Bausch Health's shares advanced after the pharmaceutical company launched a big debt-refinancing effort, with plans to offer bonds and arrange new credit facilities so it can repay an existing credit ...

His friend Henry Lomb invested his savings in Bausch's shop and in 1855 became his partner. Even with the loan, the business floundered until Bausch stumbled upon a piece of vulcanized rubber on a ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of their value on a report that a joint takeover bid for the group is in trouble. The Financial Times has said that ...

Lomb worked as a carpenter before he joined John Jacob Bausch, the owner of a retail optical shop in Rochester. Lomb invested his personal savings in the business and became Bausch's partner. On the ...

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.24 per share a year ago.

Bausch + Lomb delivered strong Q4 results, driven by growth across all segments and significant contributions from the dry eye portfolio and premium lenses. With a robust product pipeline and ...

Bausch + Lomb narrowed its loss in the fourth quarter thanks to stronger than expected revenue and expects the growth momentum to continue in 2025. The Canadian eye-health company on Wednesday ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, issued the following update on a potential sale, which was ...

Bausch + Lomb has bought US and Canadian rights to a potential biosimilar competitor to Novartis’ Lucentis from Germany’s Stada, as the blockbuster approaches the end of its patent ...